Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its upcoming fourth quarter and year-end 2022 financial results, scheduled for March 2, 2023. A press release will be issued at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases including Hepatitis B and SARS-CoV-2, with lead compound AB-729 currently in phase 2 trials. Arbutus aims to provide a functional cure for chronic HBV. Investors can access the conference call via a registration link or through the company's website.

Positive

• Scheduled financial results announcement for Q4 and year-end 2022 provides transparency.
• Continued development of AB-729, a promising candidate for chronic HBV treatment in phase 2 trials.

Negative

• None.

WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2022 financial results and corporate update for Thursday, March 2, 2023. The schedule for the press release and conference call/webcast are as follows:

•	Q4 and Year End 2022 Press Release:	Thursday, March 2, 2023 at 7:30 a.m. ET
•	Q4 and Year End 2022 Conference Call/Webcast:	Thursday, March 2, 2023 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When will Arbutus Biopharma release its Q4 and year-end 2022 financial results?

Arbutus Biopharma will release its Q4 and year-end 2022 financial results on March 2, 2023 at 7:30 a.m. ET.

What time is the Arbutus Biopharma conference call for Q4 and year-end 2022?

The conference call for Q4 and year-end 2022 is scheduled for March 2, 2023 at 8:45 a.m. ET.

What is the main focus of Arbutus Biopharma?

Arbutus Biopharma focuses on developing therapeutics for viral diseases such as Hepatitis B and SARS-CoV-2.

What is the status of AB-729 in Arbutus Biopharma's clinical trials?

AB-729 is currently being evaluated in multiple phase 2 clinical trials for the treatment of chronic Hepatitis B.